EP1331925A2 - Use of an association of at least a carotenoid and of at least an isoflavonoid for treating cutaneous symptoms of ageing - Google Patents
Use of an association of at least a carotenoid and of at least an isoflavonoid for treating cutaneous symptoms of ageingInfo
- Publication number
- EP1331925A2 EP1331925A2 EP01982556A EP01982556A EP1331925A2 EP 1331925 A2 EP1331925 A2 EP 1331925A2 EP 01982556 A EP01982556 A EP 01982556A EP 01982556 A EP01982556 A EP 01982556A EP 1331925 A2 EP1331925 A2 EP 1331925A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- composition
- carotenoid
- skin
- isoflavonoid
- intended
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/31—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the invention relates to the use in a composition or for the preparation of a composition of the combination of at least one carotenoid and at least one isoflavonoid, the combination or the composition being intended to treat skin signs of aging, in particular the degradation of the skin and / or mucous membranes by inhibiting the activity and / or expression of collagenases and by increasing the synthesis of collagen.
- the invention also relates to a method of cosmetic treatment of the skin and / or mucous membranes.
- the skin In mammals in general, particularly in humans, the skin consists of two compartments, namely a compartment in relation to the outside, the epidermis, and a deep compartment which serves to support the epidermis, the dermis.
- the epidermis is mainly composed of three types of cells which are the keratinocytes, very majority, the melanocytes and the Langerhans cells. Each of these cell types contributes by its own functions to the essential role played in the body by the skin.
- the dermis provides the epidermis with solid support. It is also its nourishing element. It mainly consists of fibroblasts and an extracellular matrix itself composed mainly of collagen, elastin and a substance, known as the fundamental substance, components synthesized by the fibroblast. There are also leukocytes, mast cells or tissue macrophages. it is also crossed by blood vessels and nerve fibers. In normal skin, that is to say non-pathological or scarring, the fibroblast is in a quiescent state, that is to say non-proliferative, not very active from a metabolic point of view and not mobile.
- Collagen fibers largely ensure the solidity of the dermis. These fibers are made up of fibrils sealed to each other, thus forming more than ten different types of structures. The solidity of the dermis is largely due to the entanglement of collagen fibers packed against each other in all directions. Collagen fibers also participate in elasticity and especially in the tone of the skin and / or mucous membranes. The collagen fibers are constantly renewed, but this renewal decreases with age, which leads to thinning of the dermis. This thinning of the dermis is also due to pathological causes such as for example the hypersecretion of corticosteroid hormones, certain pathologies or vitamin deficiencies. It is also recognized that extrinsic factors such as ultraviolet rays, tobacco or certain treatments (GlucoGorticoids, vitamin D and derivatives, for example) also have an effect on the skin and its collagen level.
- extrinsic factors such as ultraviolet rays, tobacco or certain treatments (GlucoGorticoids, vitamin D and derivatives, for
- collagen fibers are sensitive to certain enzymes called collagenases. Degradation of collagen fibers results in the appearance of soft, wrinkled skin that has always been sought to combat, particularly in humans, preferring the appearance of smooth and taut skin.
- Collagenases are part of a family of enzymes called metalloproteinases (MMPs) which are themselves members of a family of proteolytic enzymes (endoproteases) which have a zinc atom coordinated to 3 cysteine residues and a methionine in their active site and which degrade the macromolecular components of the extracellular matrix and basal laminae at neutral pH (collagen, elastin, etc.), Very widespread in the living world, these enzymes are present, but weakly expressed, in normal physiological situations like organ growth and tissue renewal,
- the family of metalloproteinases consists of several well-defined groups based on their similarities in terms of structure and substrate specificity (see Woessner J. F Faseb Journal, vol. 5, 1991, 2145).
- collagenases intended for degrading fibrillar collagens MMP-1 or interstitial collagenase, MMP-8 or collagenase of neutrophil, MMP-13 or collagenase 3
- gelatinases which degrade type IV collagen or any form of denatured collagen MMP-2 or gelatinase A (72 kDa), MMP-9 or gelatinase B (92 kDa)
- stromelysins MMP-3
- MMP-3 membrane metalloproteinases.
- Prolonged exposure to ultraviolet radiation has the effect of stimulating the expression of collagenases, particularly MMP-1, This is one of the components of skin aging photo -induit.
- the main modifications concerning the dermis are a reduction in the collagen level and the dermal thickness. This leads to a thinning of the skin and / or mucous membranes in postmenopausal women. The woman then feels a feeling of "dry skin” or of tight skin and there is an accentuation of surface wrinkles and fine lines. a rough appearance on palpation. Finally the skin has reduced flexibility
- cutaneous signs of aging means any modification of the external appearance of the skin due to aging, whether chronobiologically and / or photo-induced, such as for example wrinkles and fine lines, withered skin, mole skin, skin thinned, dull and dull skin, lack of elasticity and / or tone of the skin, but also all internal modifications of the skin which do not systematically result in a modified external appearance, such as for example all internal degradations of the skin, particularly collagen fibers, following exposure to ultraviolet radiation, which can result in thinning of the dermis,
- One of the aims of the present invention is therefore to be able to have a product which makes it possible to treat, in mammals in general, particularly in humans, preventively and / or curatively, the cutaneous signs of aging, whether chronobiological or photo-induced, particularly thinning of the dermis and / or degradation of collagen fibers, by a stimulating effect on collagen synthesis and / or a collagenase inhibiting effect and if possible no significant side effects.
- the Applicant has now discovered that the combination of at least one carotenoid and at least one isoflavonoid makes it possible to treat, in a preventive and / or curative manner, the skin signs of aging, whether chronobiological or photo- induced, particularly the thinning of the dermis and / or the degradation of collagen fibers, by a stimulating effect on collagen synthesis and / or a collagenase inhibiting effect,
- a remarkable property of the combination of the invention is that it has effects in greater proportions than those reasonably expected from the simple addition of the effects of each of these components taken separately.
- An advantage of this property is to allow a use in the composition of the invention of a quantity of each of the products less than what is generally accepted to use,
- the first object of the invention is the use in a composition or for the preparation of a composition of the combination of at least one carotenoid and at least one isoflavonoid, the combination or the composition being intended for treat the skin signs of aging.
- a second object of the invention is the use in a composition or for the preparation of a composition of the combination of at least one carotenoid and of at least one isoflavonoid, the combination or the composition being intended to combat collagen damage.
- a third object of the invention is the use in a composition or for the preparation of a composition of the combination of at least one carotenoid and at least one isoflavonoid, the combination or the composition being intended to inhibit the expression of proteases of the extracellular matrix, particularly metalloproteinases and even more particularly metalloproteinase type 1.
- a fourth object of the invention is the use of the combination in a composition or for the preparation of a composition of the combination of at least one carotenoid and at least one isoflavonoid, the combination or the composition being intended to treat cutaneous affections linked to aging, in particular cutaneous affections of the menopause.
- a fifth object of the invention is the use in a composition or for the preparation of a composition of the combination of at least one carotenoid and at least one isoflavonoid, the combination or the composition being intended to combat wrinkles and fine lines.
- a sixth object of the invention is the use in a composition or for the preparation of a composition of the combination of at least one carotenoid and at least one isoflavonoid, the combination or the composition being intended to combat withered skin.
- the seventh subject of the invention is the use in a composition or for the preparation of a composition of the combination of at least one carotenoid and at least one isoflavonoid, the combination or the composition being intended to combat soft skin.
- the eighth object of the invention is the use in a composition or for the preparation of a composition of the combination of at least one carotenoid and of at least one isoflavonoid, the combination or the composition being intended to combat thinned skin.
- the ninth object of the invention is the use in a composition or for the preparation of a composition of the combination of at least one carotenoid and at least one isoflavonoid, the combination or the composition being intended to combat dull and dull skin.
- a tenth subject of the invention is the use in a composition or for the preparation of a composition of the association of at least one carotenoid and of at least one isoflavonoid, the association or the composition being intended to combat the lack of elasticity and / or tone of the skin.
- carotenoid is meant according to the invention both a carotenoid with provitamin A activity, and a carotenoid without provitamin A activity.
- the carotenoid can be a mixture of carotenoids with provitamin A activity and carotenoids without provitamin A activity. This mixture can be in any proportion.
- the carotenoid with provitamin A activity can be a mixture of carotenoids with provitamin A activity.
- This mixture can be in any proportion.
- the carotenoids with provitamin A activity there may be mentioned, for example, ⁇ -carotene or ⁇ -carotene.
- ⁇ -carotene is used.
- the carotenoid without provitamin A activity can be a mixture of carotenoids without provitamin A activity. This mixture can be
- lycopene is used.
- a carotenoid without provitamin A activity is used, and even more preferably lycopene,
- Lycopene is a natural pigment found in ripe fruit, especially in tomatoes. It belongs to the carotenoid family and its structure is close to that of ⁇ -carotene,
- lycopene is used in compositions with tanning activity for its role on the synthesis of melanin (WO 97/47278), in compositions intended for the treatment of the hair and / or acne for its activity on 5 ⁇ -reductases (JP-2940964) or also as an anti-radical agent (JP -A-8-283136.
- the lycopene can be in the cis or trans chemical form,
- the carotenoid used according to the invention may be of natural or synthetic origin
- natural origin is meant the carotenoid, in the pure state or in solution whatever its concentration in said solution, obtained from a natural element.
- an extract rich in lycopene is used, such as for example a tomato extract.
- the carotenoid When the carotenoid is of natural origin, it can be obtained from plant material from a whole plant grown in vivo or from in vitro culture.
- in vivo culture means any conventional type culture, that is to say in soil in the open air or in a greenhouse, or even above ground,
- in vitro culture means all of the techniques known to those skilled in the art which artificially make it possible to obtain a plant or part of a plant.
- the selection pressure imposed by the physicochemical conditions during the growth of plant cells in vitro makes it possible to obtain standardized plant material which is available throughout the year, unlike plants cultivated in vivo.
- a plant derived from culture in vivo is used.
- the carotenoid can be in alcoholic solution, in particular ethanolic.
- the carotenoid can also be in lipid (oil) or lipoalcoholic solution.
- lipid oil
- lipoalcoholic solution a tomato extract rich in lycopene is used, prepared by the company Métaphar, marketed under the name LycOMato® consisting of an oleoresin extract (fatty phase) containing 6% of pure lycopene. .
- any preparation containing lycopene having the objective of improving the bioavailability of the latter and / or all new processes for the manufacture and / or formulation and / or encapsulation of Lycopene,
- the amount of carotenoid that can be used according to the invention is of course a function of the desired effect and can therefore vary to a large extent
- the carotenoid in the pure state is in an amount representing from 10 "1 % to 20% of the total weight of the composition and preferably in An amount representing from 10 " 10 % to 10% of the total weight of the composition.
- Isoflavonoids constitute a subclass of flavonoids, formed of a 3-phenyl chroman skeleton which can include various substituents and different levels of oxidation. Unlike flavonoids, they are only found in a very limited number of plants.
- isoflavonoid includes several classes of compounds among which there may be mentioned isoflavones, isoflavanones, rotenoids, pterocarpans, isoflavanes, isoflavanes-3-enes, 3-arylcoumarins, 3-aryl-4-hydroxycoumarins, coumestanes, coumaronochromones, ⁇ -methyldeoxybenzoines or 2-arylbenzofurans.
- the isoflavonoids suitable for use in the present invention may be of natural or synthetic origin
- natural origin means the isoflavonoid in the pure state or in solution at different concentrations, obtained by different methods of extraction from an element, generally a plant, of natural origin
- synthetic origin means the isoflavonoid in the pure state or in solution at different concentrations, obtained by chemical synthesis.
- isoflavonoids of natural origin it is preferred to use isoflavonoids of natural origin.
- the isoflavones it is preferred to use the isoflavones.
- the simplest forms of aglycones including daidzein, genistein and their mixture. These two compounds are especially present in the soy extract (Glycina max) available from Archer Daniels Midland Company under the name Novasoy®. 20
- the amount of isoflavonoid that can be used according to the invention is of course a function of the desired effect and can therefore vary to a large extent
- the isoflavonoid in the pure state is in an amount representing from 10 "10 % to 10% of the total weight of the composition and preferably in an amount representing from 10 "8 % to 5% of the total weight of the composition.
- isoflavonoid is present in the form of a solution, for example a plant extract
- a person skilled in the art will be able to adjust the amount of this solution in the composition according to the invention, so as to obtain the ranges of concentrations in isoflavonoid described above.
- Isoflavones are in particular known as antioxidants, for their anti-radical and de-increasing properties, as well as for inhibiting the activity sebaceous glands (see in particular DE-44 32 947).
- composition of the invention can be in any conceivable dosage form, suitable for both topical application to the skin and / or mucous membranes and / or hair and / or body hair as for administration by the oral route,
- composition of the invention is intended for administration by the oral route.
- the composition of the invention may be a cosmetic or dermatological composition.
- the composition is a cosmetic composition.
- the composition is a cosmetic composition because it is intended to improve the general cutaneous appearance of the individual who uses it.
- the composition of the invention is a cosmetic composition intended for administration by the oral route.
- the composition of the invention can be in any suitable form, particularly in the form of an oral solution, a syrup, a tablet, a dragee, a capsule or a capsule or a nutritional food or nutritional supplement.
- composition can also comprise at least one suitable excipient suitable for oral administration,
- the composition according to the invention obviously comprises a cosmetically acceptable support, that is to say a support compatible with the skin, mucous membranes, nails, hair, hair and can be in all dosage forms normally used for a topical application, in particular in the form of an aqueous, hydroalcoholic or oily solution, of an oil-in-water or water emulsion -in-oil or multiple, of an aqueous or oily gel, of an anhydrous liquid, pasty or solid product, of an oil dispersion in an aqueous phase using spherules, these spherules possibly being nanoparticles polymers such as nanospheres and nanocapsules or better lipid vesicles of ionic and / or non-ionic type.
- a cosmetically acceptable support that is to say a support compatible with the skin, mucous membranes, nails, hair, hair and can be in all dosage forms normally used for a topical application, in particular in the form of an aqueous, hydroalcoholic or oily
- This composition can be more or less fluid and have the appearance of a white or colored cream, an ointment, a milk, a lotion, a serum, a paste, a foam. . It can optionally be applied to the skin in the form of an aerosol. It can also be in solid form, and for example in the form of a stick. It can be used as a care product, as a cleaning product, as a makeup product or even as a simple deodorant product.
- the composition of the invention may contain the adjuvants usual in the cosmetic and dermatological fields, such as hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active agents, preservatives, antioxidants, solvents, perfumes, fillers , filters, pigments, chelating agents, odor absorbers and coloring matter.
- the amounts of these various adjuvants are those conventionally used in the fields considered, and for example from 0.01% to 20% of the total weight of the composition.
- These adjuvants depending on their nature, can be introduced into the fatty phase, into the aqueous phase, into the lipid esicles and / or into the nanoparticles.
- the proportion of the fatty phase can range from 5% to 80% by weight, and preferably from 5% to 50% of the total weight of the composition.
- the oils, emulsifiers and co-emulsifiers used in the composition in the form of an emulsifier are chosen from those conventionally used in the field under consideration.
- the emulsifier and the coemulsifier are present in the composition in a proportion ranging from 0.3% to 30% by weight, and preferably from 0.5% to 20% of the total weight of the composition,
- emulsifiers and co-emulsifiers which can be used in the invention, mention may, for example, be made of fatty acid and polyethylene glycol esters such as PEG-40 stearate, PEG-100 stearate, fatty acid and polyol esters such as glyceryl stearate and sorbitane tristearate,
- hydrophilic gelling agents mention may be made in particular of carboxyvinyl polymers (carbomers), acrylic copolymers such as acrylate / alkyl acrylate copolymers, polyacrylamides, polysaccharides, natural gums and clays, and, as lipophilic gelling agents, cite modified clays such as bentones, metal salts of fatty acids, hydrophobic silica and polyethylenes.
- composition can contain other hydrophilic active agents such as proteins or protein hydrolysates, amino acids, polyols, urea, allantoin, sugars and sugar derivatives, plant extracts and hydroxy acids.
- hydrophilic active agents such as proteins or protein hydrolysates, amino acids, polyols, urea, allantoin, sugars and sugar derivatives, plant extracts and hydroxy acids.
- vitamin A retinol
- vitamin E tocopherol
- essential fatty acids ceramides
- essential oils salicylic acid and its derivatives or vitamins
- vitamin C or ascorbic acid
- its derivatives esters, salts, etc.
- a preferred composition of the invention comprises, among other ingredients, the combination of at least one carotenoid and at least one isoflavonoid, an extract of vitamin C and ⁇ -tocopherol.
- the composition of the invention comprises, among other ingredients, the combination of ⁇ -carotene, soy extract (Novasoy® from the company Archer Daniels Midland Company), vitamin C and acetate d ' ⁇ -tocopherol.
- - calcium antagonists such as verapamil and Diltiazem
- - OH radical sensors such as dimethylsulfoxide
- - plant extracts extracts of micro-organisms including in particular bacterial extracts such as those of non-filamentous bacteria Photosynthetic.
- potassium channel openers such as diazoxide and minoxidil, spiroxazone, phospholipids such as lecithin, linoleic and linolenic acids, salicylic acid and its derivatives described in French patent FR 2,581,542, such as salicylic acid derivatives carrying an alkanoyl group having from 2 to 12 carbon atoms in position, 5 of the benzene ring, hydroxycarboxylic or ketocarboxylic acids and their esters, lactones and their corresponding salts, anthralin, carotenoids, eicosatetraenoic and eicosatrienoic acids or their esters and amides, vitamin D and its derivatives,
- potassium channel openers such as diazoxide and minoxidil, spiroxazone, phospholipids such as lecithin, linoleic and linolenic acids, salicylic acid and its derivatives described in French patent FR 2,581,542, such as salicylic acid derivative
- composition of the invention it is possible, among other things, to add to the composition of the invention other active agents intended in particular for the prevention and / or treatment of skin conditions.
- active agents there may be mentioned by way of example:
- agents modulating differentiation and / or proliferation and / or skin pigmentation such as retinoic acid and its isomers, retinol and its esters, vitamin D and its derivatives, estrogens such as estradiol, kojic acid or hydroquinone;
- - antibacterials such as clindamycin phosphate, perythromycin or antibiotics of the tetracycline class
- - agents modulating bacterial adhesion to the skin and / or mucous membranes such as honey, in particular acacia honey and certain sugar derivatives; - antiparasitic agents, in particular metronidazole, crotamiton or pyrethroids;
- - antifungals in particular compounds belonging to the class of imidazoles such as econazole, ketoconazole or miconazole or their salts, polyene compounds, such as amphotericin B, compounds of the allylamine family, such as terbinafine, or octopirox;
- - antiviral agents such as acyclovîr
- - steroidal anti-inflammatory agents such as hydrocortisone, betamethasone valerate or clobetasol propionate, or non-steroidal anti-inflammatory agents such as ibuprofen and its salts, diclofenac and its salts, acetylsalicylic acid , acetaminophen or glycyrrhetinic acid;
- - anesthetic agents such as lidocaine hydrochloride and its derivatives
- - antipruritic agents such as thenaldine, trimeprazine or cyproheptadine
- - keratolytic agents such as alpha- and beta-hydroxycarboxylic or beta-ketocarboxylic acids, their salts, amides or esters and more particularly hydroxy acids such as glycolic acid, lactic acid, salicylic acid, l citric acid and generally fruit acids, and n-octanoyl-5-salicylic acid;
- - anti-free radical agents such as superoxide dismutases, certain metal chelators or ascorbic acid and its esters;
- - dandruff like octopîrox or zinc pyrith ⁇ one
- - anti-acne drugs such as retinoic acid or benzoyl peroxide
- compositions such as antagonists of substance P, of CGRP or of bradykinin or inhibitors of NO synthase or also inhibitors of sodium channels, compounds described as being active in the treatment of sensitive skin and as having anti-irritant effects, in particular with regard to irritant compounds possibly present in the compositions.
- moisturizers such as polyols (for example glycerin), vitamins (for example D-panthenol), anti-inflammatory agents, soothing agents (allantoin, blueberry water), filters can be used UVA and UVB, matting agents (for example partially crosslinked polydimethylorganosiloxanes sold under the name KSG® by Shin Etsu) and their mixtures,
- polyols for example glycerin
- vitamins for example D-panthenol
- anti-inflammatory agents for example D-panthenol
- soothing agents allantoin, blueberry water
- filters can be used UVA and UVB, matting agents (for example partially crosslinked polydimethylorganosiloxanes sold under the name KSG® by Shin Etsu) and their mixtures,
- Anti-wrinkle active agents can also be added, and in particular tensing products such as vegetable proteins and their hydrolysates, in particular the soy protein extract sold under the name Eleseryl® by the company LSN or the oat derivative sold. under the name Reduct Sciencee® by the company Silab.
- the skin is made up of many other components than collagen and fibroblasts, it turns out to be advantageous, when using the combination of the invention, to promote at the same time the synthesis of these other components such as for example lipids and / or promote the proliferation of other cellular components such as, for example, keratinocytes.
- the subject of the invention is a cosmetic composition
- a cosmetic composition comprising in a cosmetically acceptable medium the combination of at least one carotenoid and at least one isoflavonoid and at least one other product stimulating the synthesis of lipids and / or the proliferation of keratinocytes
- the carotenoid and the isoflavonoid can be as described previously in the text,
- Said composition can be intended for use in the cosmetic or dermatological field, preferably in the cosmetic field.
- Mention may be made, as product stimulating the synthesis of lipids, of plant hormones, such as auxins, or of compounds of vegetable origin, such as cinnamic acid, and as product stimulating the proliferation of keratinocytes of compounds of vegetable origin, such as phloroglucinol. ,
- compositions according to the invention can comprise, in addition to the combination of the invention, cinnamic acid or its derivatives and / or a plant hormone, particularly an auxin chosen from indolacetic acid (IAA), l 4-chloroindole-3-acetic acid (4-Cl-lAA), phenylacetic acid (PAA), indole-3-butyric acid (I BA), 2,4-dichlorophenoxyacetic acid (2,4 -D), ⁇ -naphthalene acetic acid (-NAA), ⁇ -naphthoxyacetic acid, indole ethanol, idol acetaldehyde and indole acetonitrile and / or a plant compound such as phloroglucinol.
- auxin chosen from indolacetic acid (IAA), l 4-chloroindole-3-acetic acid (4-Cl-lAA), phenylacetic acid (PAA), indole-3-butyric acid
- Another subject of the invention is the use of the combination of at least one carotenoid, at least one isoflavonoid and at least one other product stimulating the synthesis of lipids and / or the proliferation of keratinocytes in a composition. or for the preparation of a composition, the combination or the composition being intended to treat, preventively and / or curatively, the cutaneous signs of aging, to combat collagen deterioration, to inhibit the expression of the extracellular matrix, to inhibit the expression of metalloproteinases, particularly metalloproteinase type 1, to treat skin disorders linked to menopause, to fight against fine lines and wrinkles, to fight against withered skin, to fight against soft skin , to fight against thinned skin, to fight against dull and / or dull skin, to fight against the lack of elasticity and / or tone of the skin, to fight against d internal skin damage following exposure to ultraviolet radiation.
- metalloproteinases particularly metalloproteinase type 1
- compositions according to the invention can comprise, in addition to the combination of the invention, cinnamic acid or its derivatives and / or a plant hormone, particularly an auxin chosen from indolacetic acid (IAA), l 4-chloroindole-3-acetic acid (4-CI-IAA), phenylacetic acid (PAA), indole-3-butyric acid (IBA), 2,4-dichlorophenoxyacetic acid (2,4- D), ⁇ -naphthalene acetic acid ( ⁇ -NAA), ⁇ -naphthoxyacetic acid, indole ethanol, idol acetaldehyde and indole acetonitrile and / or a plant compound such as phloroglucinol
- auxin chosen from indolacetic acid (IAA), l 4-chloroindole-3-acetic acid (4-CI-IAA), phenylacetic acid (PAA), indole-3-butyric acid (IBA
- the present invention further relates to a method of cosmetic treatment of the skin intended to stimulate the synthesis of collagen and / or fight against skin disorders linked to age and / or menopause and / or fight against thinning. of the dermis and / or combat the appearance of soft and / or wrinkled skin, characterized in that it is applied to the skin, on the hair, on the hair and / or on the mucous membranes or that is ingested a cosmetic composition comprising at least the combination of at least one carotenoid and at least one isoflavonoid.
- the cosmetic treatment process of the invention can be implemented in particular by applying the cosmetic compositions as defined above, according to the technique of usual use of these compositions.
- cosmetic compositions as defined above, according to the technique of usual use of these compositions.
- compositions illustrate the invention without limiting it in any way.
- proportions indicated are percentages by weight
- Composition 1 Soft capsules; Excipients.
- Composition 2 Lotion
- Lycopene 6% (Lycomato®) 0.001%
- Antioxidant 0.05% Isopropanol 40.0%
- Composition 3 Care cream (oil in water emulsion) Lycopene 6% (Lycomato®) 0.005%
- Vitamin C " 5.00%
- Polysorbate 60 (Tween 60 ® sold by the company ICI) 1.00% Stearic acid 1.40% 0
- composition 4 Care cream (oil-in-water emulsion)
- Lycopene 6% (Lycomato®) 0.001%
- Polysorbate 60 (Tween 60 ® sold by the company ICI) 1.00%
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0013755A FR2815861B1 (en) | 2000-10-26 | 2000-10-26 | USE OF THE COMBINATION OF AT LEAST ONE CAROTENOID AND AT LEAST ONE ISOFLAVONOID FOR TREATING SKIN SIGNS OF AGING |
FR0013755 | 2000-10-26 | ||
PCT/FR2001/003319 WO2002034233A2 (en) | 2000-10-26 | 2001-10-25 | Use of an association of a carotenoid and of an isoflavonoid for treating cutaneous symptoms of ageing |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1331925A2 true EP1331925A2 (en) | 2003-08-06 |
Family
ID=8855771
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP01982556A Withdrawn EP1331925A2 (en) | 2000-10-26 | 2001-10-25 | Use of an association of at least a carotenoid and of at least an isoflavonoid for treating cutaneous symptoms of ageing |
Country Status (6)
Country | Link |
---|---|
US (2) | US20040071745A1 (en) |
EP (1) | EP1331925A2 (en) |
JP (2) | JP2004512295A (en) |
AU (1) | AU2002214106A1 (en) |
FR (1) | FR2815861B1 (en) |
WO (1) | WO2002034233A2 (en) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10139792A1 (en) * | 2001-08-14 | 2003-02-27 | Beiersdorf Ag | Use of tectorigenin for the production of cosmetic or dermatological preparations for the prophylaxis and treatment of inflammatory skin conditions and / or for skin protection in sensitive, dry skin |
DE10301631A1 (en) * | 2003-01-17 | 2004-07-29 | Beiersdorf Ag | Cosmetic and dermatological composition, useful e.g. for restructuring and rejuvenating skin, contains soya bean germ extract, vitamins C and E and alpha-glycosylrutin |
FR2854897B1 (en) * | 2003-05-12 | 2007-05-04 | Sederma Sa | COSMETIC OR DERMOPHARMACEUTICAL COMPOSITIONS FOR REDUCING THE SIGNS OF SKIN AGING. |
DE10356864A1 (en) * | 2003-12-03 | 2005-07-07 | Beiersdorf Ag | Cosmetic and dermatological preparations containing licochalcone A and soybean germ extracts |
KR100739531B1 (en) * | 2004-05-07 | 2007-07-13 | 주식회사 이오텍 | Compositions Comprising Lycopene and Phytoestrogen |
MX2008010716A (en) | 2006-02-21 | 2008-10-14 | Mary Kay Inc | Stable vitamin c compositions. |
EP1958611A1 (en) * | 2006-12-20 | 2008-08-20 | DSMIP Assets B.V. | Oral composition containing EGCG and lycopene |
US20090162306A1 (en) * | 2007-12-21 | 2009-06-25 | Conopco, Inc., D/B/A Unilever | Topical composition comprising coloring antioxidants |
FR2944437B1 (en) * | 2009-04-16 | 2013-05-10 | Oreal | USE OF HIF 1 ALPHA EXPRESSION INHIBITORS TO PROTECT THE SKIN FROM DERMAL DAMAGE INDUCED BY UVA RADIATION |
FR2974300B1 (en) * | 2011-04-19 | 2013-05-10 | Inneov Lab | USE OF A COMBINATION OF A CAROTENOID, A PHYTOESTROGEN AND VITAMIN C FOR THE PREVENTION AND / OR TREATMENT OF PIGMENT DISORDERS |
FR2974296B1 (en) * | 2011-04-19 | 2013-05-24 | Inneov Lab | USE OF A COMBINATION OF A CAROTENOID, A PHYTOESTROGEN AND VITAMIN C AS AN AGENT FOR HYDRATION OF THE SKIN |
JP2013126965A (en) * | 2011-11-14 | 2013-06-27 | Fujifilm Corp | Nrf2 ACTIVATOR FOR NORMAL SKIN CELL |
FR2996135A1 (en) * | 2012-09-28 | 2014-04-04 | Inneov Lab | ORAL COMPOSITION FOR ENHANCING SKIN TOLERANCE FOLLOWING TOPICAL ADMINISTRATION OF RETINOID COMPOUND |
JP6426902B2 (en) * | 2014-03-20 | 2018-11-21 | 株式会社コーセー | Carotenoid-Containing Composition, Carotenoid Deterioration Inhibitor, and Carotenoid Deterioration Suppression Method |
IT201700114744A1 (en) * | 2017-10-11 | 2019-04-11 | Cristina Chiuso | Polyphenolic formulation for skin and hair protection |
KR102322836B1 (en) * | 2018-12-14 | 2021-11-10 | 경희대학교 산학협력단 | Cosmetic composition for antiaging or skin wrinkle containing tectorigenin |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05320036A (en) * | 1992-05-19 | 1993-12-03 | Shiseido Co Ltd | Composition for eliminating singlet oxygen |
US5567454A (en) * | 1994-07-13 | 1996-10-22 | Bogdan; Jeffrey A. | Nut butter and jelly food slice |
DE4444238A1 (en) * | 1994-12-13 | 1996-06-20 | Beiersdorf Ag | Cosmetic or dermatological drug combinations of cinnamic acid derivatives and flavone glycosides |
US5824702A (en) * | 1996-06-07 | 1998-10-20 | Mount Sinai School Of Medicine Of The City University Of New York | Genistein as a preventive against ultraviolet induced skin photodamage and cancer |
TWI234467B (en) * | 1997-06-04 | 2005-06-21 | Univ Michigan | Composition for inhibiting photoaging of skin |
US6060070A (en) * | 1997-06-11 | 2000-05-09 | Gorbach; Sherwood L. | Isoflavonoids for treatment and prevention of aging skin and wrinkles |
US5904924A (en) * | 1997-11-04 | 1999-05-18 | Oncologics, Inc. | Green nutritional powder composition |
FR2772609B1 (en) * | 1997-12-19 | 2004-05-07 | Oreal | USE OF AT LEAST ONE AUXIN IN A COSMETIC COMPOSITION |
AUPP112497A0 (en) * | 1997-12-24 | 1998-01-22 | Novogen Research Pty Ltd | Compositions and method for protecting skin from UV induced immunosupression and skin damage |
JP2002506807A (en) * | 1998-03-16 | 2002-03-05 | ザ、プロクター、エンド、ギャンブル、カンパニー | How to adjust skin appearance |
US5972993A (en) * | 1998-03-20 | 1999-10-26 | Avon Products, Inc. | Composition and method for treating rosacea and sensitive skin with free radical scavengers |
AT407821B (en) * | 1998-03-24 | 2001-06-25 | Franz Dr Stueckler | MEDIUM BASED ON NATURAL SUBSTANCES |
US6150399A (en) * | 1998-06-30 | 2000-11-21 | Abbott Laboratories | Soy-based nutritional products |
DE19838636A1 (en) * | 1998-08-26 | 2000-03-02 | Basf Ag | Carotenoid formulations containing a mixture of beta-carotene, lycopene and lutein |
FR2782919B1 (en) * | 1998-09-04 | 2001-05-25 | Roc Sa | COMPOSITION AGAINST AGING AND ITS USE |
US6630160B1 (en) * | 1999-09-07 | 2003-10-07 | Genetic Services Management, Inc. | Process to modulate disease risk with doses of a nutraceutical |
US20050031557A1 (en) * | 1999-09-08 | 2005-02-10 | Christine Gaertner | Oral administration of beta-carotene, lycopene and lutein for human skin protection |
WO2001037781A2 (en) * | 1999-10-28 | 2001-05-31 | Ingredient Innovations International | A stable aqueous dispersion of nutrients |
ATE324800T1 (en) * | 2000-05-30 | 2006-06-15 | Nestle Sa | PRIMARY COMPOSITION CONTAINING A LIPOPHILIC BIOACTIVE SUBSTANCE |
-
2000
- 2000-10-26 FR FR0013755A patent/FR2815861B1/en not_active Expired - Fee Related
-
2001
- 2001-10-25 EP EP01982556A patent/EP1331925A2/en not_active Withdrawn
- 2001-10-25 WO PCT/FR2001/003319 patent/WO2002034233A2/en active Application Filing
- 2001-10-25 JP JP2002537287A patent/JP2004512295A/en not_active Withdrawn
- 2001-10-25 AU AU2002214106A patent/AU2002214106A1/en not_active Abandoned
-
2003
- 2003-04-28 US US10/424,128 patent/US20040071745A1/en not_active Abandoned
-
2008
- 2008-02-22 JP JP2008040942A patent/JP2008189675A/en not_active Withdrawn
- 2008-05-19 US US12/122,943 patent/US20090105330A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
See references of WO0234233A2 * |
Also Published As
Publication number | Publication date |
---|---|
WO2002034233A2 (en) | 2002-05-02 |
JP2004512295A (en) | 2004-04-22 |
FR2815861A1 (en) | 2002-05-03 |
US20040071745A1 (en) | 2004-04-15 |
FR2815861B1 (en) | 2003-02-28 |
WO2002034233A3 (en) | 2002-08-29 |
US20090105330A1 (en) | 2009-04-23 |
AU2002214106A1 (en) | 2002-05-06 |
JP2008189675A (en) | 2008-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1064931B1 (en) | Cosmetic composition containing at least one hydroxystilbene and ascorbic acid | |
EP1090628B1 (en) | Use of lycopene in compositions for treating ageing skin symptoms | |
EP0953346B1 (en) | Use of at least a hydroxystilbene in a skin fortifying composition | |
EP1195156A1 (en) | Use of an ericaceae extract in skin-ageing treatment | |
CA2255229C (en) | Use of cinnamic acid, or of its derivatives, as a firming agent in a cosmetic composition | |
US20090105330A1 (en) | Admixture of carotenoids and isoflavonoids for treating cutaneous symptoms of aging | |
US20090227688A1 (en) | Admixture of carotenoids having provitamin a activity and carotenoids devoid of provitamin a activity for treating aging symptoms | |
FR2812544A1 (en) | Treatment of cutaneous aging symptoms, such as wrinkles, comprises topical or oral administration of Salvia genus plant extracts with collagenase expression inhibiting activity | |
CA2478783A1 (en) | Compound to prevent and/or fight the breakdown of collagen constructs when exposed to natural sunlight | |
WO2002034210A2 (en) | Use of the association of at least a carotenoid and vitamin c for treating cutaneous symptoms of ageing | |
US20090123573A1 (en) | Admixture of extracts of plants of the genus rosmarinus and carotenoids for treating cutaneous symptoms of aging | |
FR2821549A1 (en) | Use of a carotenoid to increase dermal collagen and lessen or prevent signs of cutaneous aging | |
WO2002034276A2 (en) | Use of the association of at least a plant extract of the genus camellia and of at least a carotenoid | |
FR2829388A1 (en) | Use of carotenoids in cosmetic compositions e.g. for stimulating keratinocyte proliferation, inhibiting keratinocyte differentiation, promoting epidermal renewal or regeneration or promoting wound healing | |
FR2772611A1 (en) | Cosmetic compositions containing auxin, preferably beta-naphthoxyacetic acid, to stimulate collagen synthesis, useful e.g. for combating cutaneous aging |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20030526 |
|
AK | Designated contracting states |
Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
17Q | First examination report despatched |
Effective date: 20060914 |
|
17Q | First examination report despatched |
Effective date: 20060914 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: NESTEC S.A. Owner name: L'OREAL |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20111028 |